{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/management/end-stage-copd/","result":{"pageContext":{"chapter":{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD","depth":2,"htmlHeader":"<!-- begin field b31e67c6-f77a-4a44-b1cd-10b323b25265 --><h2>Scenario: End-stage chronic obstructive pulmonary disease</h2><!-- end field b31e67c6-f77a-4a44-b1cd-10b323b25265 -->","summary":"Covers the management of people with COPD that is very severe, unresponsive to usual medical treatment, and associated with a likely life expectancy of less than 6–12 months.","htmlStringContent":"<!-- begin item 8ee84741-3b85-49dd-b7f4-e9dc3439f4a4 --><!-- begin field 339dd05e-3573-4907-832b-acd900adb50c --><p>From age 16 years onwards.</p><!-- end field 339dd05e-3573-4907-832b-acd900adb50c --><!-- end item 8ee84741-3b85-49dd-b7f4-e9dc3439f4a4 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c7630ba1-9302-5d29-9975-93aaf31b396f","slug":"defining-end-stage-copd","fullItemName":"Defining end-stage COPD","depth":3,"htmlHeader":"<!-- begin field 6301c02f-888b-42ae-8eb9-247a4c49f5e1 --><h3>When should I suspect a person has end-stage COPD?</h3><!-- end field 6301c02f-888b-42ae-8eb9-247a4c49f5e1 -->","summary":null,"htmlStringContent":"<!-- begin item 8eda72f8-beee-4b34-992d-147a68e5f466 --><!-- begin field a4dff7bb-cc74-4c63-b4f7-9d6f6b1a5cfc --><ul><li>There is no commonly accepted definition of “end-stage COPD” and prediction of life expectancy in COPD is difficult. In most people, disease progression will follow a course of gradual decline punctuated by acute exacerbations which increase the risk of dying.</li><li>Factors associated with increased risk of mortality in people with COPD include:<ul><li>Frequency and severity of exacerbations.</li><li>Hospitalization during an exacerbation.</li><li>Poor lung function on spirometry.</li><li>Low body mass index.</li><li>Comorbidities such as cardiovascular disease and malignancy.</li></ul></li><li>Tools, such as those from the <a data-hyperlink-id=\"e0bb04ac-ac32-4094-88d8-ab130137725f\" href=\"http://www.goldstandardsframework.org.uk/\" target=\"_blank\">Gold Standards Framework</a> are available help healthcare professionals identify people who are likely to be approaching the end of their life.</li></ul><!-- end field a4dff7bb-cc74-4c63-b4f7-9d6f6b1a5cfc --><!-- end item 8eda72f8-beee-4b34-992d-147a68e5f466 -->","subChapters":[{"id":"380d66c7-3bd6-5fc4-bc88-ad68f182983c","slug":"basis-for-recommendation-3c9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5e4e3683-bd42-44ba-94f6-dfbe2dd7842d --><h4>Basis for recommendation</h4><!-- end field 5e4e3683-bd42-44ba-94f6-dfbe2dd7842d -->","summary":null,"htmlStringContent":"<!-- begin item 3c9fa14e-51fe-4bb7-9881-fba91099a3a9 --><!-- begin field 97cd43bb-805d-463e-b635-403c0aff4a15 --><p>The information on end-stage COPD is based on clinical guidelines <em>COPD-X: concise guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Lung Foundation Australia, 2017</a>] and <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 repor</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and expert opinion in articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Bloom, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Rothnie, 2018</a>].</p><ul><li>The National Institute for Health and Care Excellence (NICE) clinical guideline on <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] does not provide an explicit definition of end-stage COPD.</li></ul><!-- end field 97cd43bb-805d-463e-b635-403c0aff4a15 --><!-- end item 3c9fa14e-51fe-4bb7-9881-fba91099a3a9 -->","subChapters":[]}]},{"id":"1c498814-aa0c-506a-8975-0cfa0c0f06b1","slug":"how-should-i-manage-a-person-with-end-stage-copd","fullItemName":"How should I manage a person with end-stage COPD?","depth":3,"htmlHeader":"<!-- begin field 5768e4d0-ff0d-4a8d-a802-5c9995cc2647 --><h3>How should I manage a person with end-stage COPD?</h3><!-- end field 5768e4d0-ff0d-4a8d-a802-5c9995cc2647 -->","summary":null,"htmlStringContent":"<!-- begin item ae8fd9f9-b5c1-4393-9bb7-be7a00f0a670 --><!-- begin field 615f9d5b-4695-451e-b10d-dd210146c06c --><ul><li>For people with end-stage COPD, the focus is on palliative care to relieve symptoms and improve quality of life.</li><li>Ensure the person has an <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/end-stage-copd/#advance-decisions\">advance care plan</a> (if they wish) and discuss end-of-life issues (where appropriate) including <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/end-stage-copd/#advance-decisions\">advance decisions</a>.<ul><li>Choosing the right time to discuss prognosis and the person’s views on care can be difficult. However, early discussion and good <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/end-stage-copd/#advance-decisions\">advance palliative care planning</a> is important in reducing anxiety for the person and their family/carer(s) and ensuring that care is consistent with wishes.</li><li>Advance care plans should be reviewed whenever there is a clinical event, deterioration, or change in social circumstances (for example a move into supported care).</li></ul></li><li>Coordinate care with a respiratory nurse specialist, district nurse, palliative care team, and social services as appropriate.</li><li>Optimize treatment associated with COPD symptoms such as:<ul><li>Breathlessness:<ul><li>Discuss simple measures (such keeping the room cool, improving air circulation with a fan or open window, and relaxation and breathing techniques) to help relieve breathlessness.</li><li>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/management/end-stage-copd/#drug-treatments-for-breathlessness\">drug treatments</a> (such as opiates) and oxygen.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/\">Palliative care - dyspnoea</a>.</li></ul></li><li>Cough — for information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-cough/\">Palliative care - cough</a>.</li><li>Secretions — for information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-secretions/\">Palliative care - secretions</a>.</li><li>Pain — for information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/\">Palliative cancer care - pain</a>.</li><li>Insomnia — for information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>.</li><li>Depression — for information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li><li>Anxiety — for information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li></ul></li><li>Discuss with a specialist/consider admission to a hospice if symptoms are not controlled, or if this is the preferred place of death.<ul><li>For general information on end-of-life care, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>.</li></ul></li><li>Consider what practical and emotional support can be provided to family/carers of people with end stage COPD.</li></ul><!-- end field 615f9d5b-4695-451e-b10d-dd210146c06c --><!-- end item ae8fd9f9-b5c1-4393-9bb7-be7a00f0a670 -->","subChapters":[{"id":"ace045b8-7844-5923-9cd5-50a53a59e520","slug":"drug-treatments-for-breathlessness","fullItemName":"Drug treatments for breathlessness","depth":4,"htmlHeader":"<!-- begin field eddf9c58-f5b4-4e46-9a22-7682fdf4cc83 --><h4>Drug treatments for breathlessness</h4><!-- end field eddf9c58-f5b4-4e46-9a22-7682fdf4cc83 -->","summary":null,"htmlStringContent":"<!-- begin item 56445ff1-0686-4254-811e-593309c6fe42 --><!-- begin field 267ebdb2-acb7-4278-9b52-ac34e93018c9 --><ul><li>When appropriate, offer opioids to relieve breathlessness in people with end-stage COPD that is unresponsive to other medical therapy.</li><li>Benzodiazepines, tricyclic antidepressants, major tranquillisers or oxygen may also be considered where appropriate for breathlessness in people with end-stage COPD that is unresponsive to other medical therapy.<ul><li>Benzodiazepines — seek specialist advice, or for more information see recommendations in the section on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/management/symptomatic-treatment/#when-to-consider-benzodiazepines\">Benzodiazepines</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/\">Palliative care - dyspnoea</a>.</li><li>Oxygen (if the person is not already on long-term oxygen therapy [LTOT]) — seek specialist advice, or for more information see recommendations in the section <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/management/symptomatic-treatment/#when-to-consider-oxygen\">When to consider oxygen</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/\">Palliative care - dyspnoea</a>.</li></ul></li><li>Seek advice from the palliative care team or specialist respiratory nurses if unsure or if measures in primary care fail.</li></ul><!-- end field 267ebdb2-acb7-4278-9b52-ac34e93018c9 --><!-- end item 56445ff1-0686-4254-811e-593309c6fe42 -->","subChapters":[]},{"id":"4e263e9a-e814-5bd4-aee2-5864629ae50c","slug":"advance-decisions","fullItemName":"Advance decisions","depth":4,"htmlHeader":"<!-- begin field a24f3eb1-9f8e-4b12-9f24-de84eb93f63c --><h4>Advance care planning and advance decisions</h4><!-- end field a24f3eb1-9f8e-4b12-9f24-de84eb93f63c -->","summary":null,"htmlStringContent":"<!-- begin item 1b892351-c177-4916-a9f8-b7209e4b1989 --><!-- begin field 8e0730d2-ce36-40b1-bb98-cf049b9a15d6 --><h5>Advance care planning</h5><ul><li>Advance care planning involves discussion about future care and support needs, including medical treatment. Discussion should cover the person’s:<ul><li>Understanding of their illness and prognosis.</li><li>Concerns and preferences for future treatment and care including:<ul><li>Preferred place of care.</li><li>When, who, and how to call for help when there is a crisis or acute exacerbation, and management options.</li><li>Discontinuation of inappropriate interventions.</li><li>Interventions which might be considered in an emergency, for example, anticipatory medications.</li><li>Whether resuscitation should be attempted if they were to have a life-threatening deterioration — this information should be made available to out-of-hours and ambulance services.</li><li>Support of their family/carers.</li></ul></li><li>Needs for psychological and spiritual care.</li></ul></li><li>Copies of advance care plans should be available in the person’s home or with them if admitted to hospital, care home or hospice.</li><li>For more information on advance care planning, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/management/communication/#important-communication-issues\">Important communication issues</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>.</li><li>The usefulness of advance decisions in chronic obstructive pulmonary disease (COPD) may be limited because:<ul><li>It is rarely feasible to give precise instructions for all potential eventualities.</li><li>The person's views and values may change over time in response to the increasing severity of disease or during an exacerbation.</li></ul></li></ul><p><strong>Advance decisions</strong> — advance decisions allow a person to state in advance (before they have lost the capacity to decide) how they wish to be treated if they lose capacity.</p><ul><li>Advanced decisions can be written documents, witnessed oral statements, signed printed cards, smart cards or a note of a particular discussion recorded in the person’s records. In England and Wales, the decision should comply with the provisions of the Mental Capacity Act if it is to be legally binding. In Scotland and Northern Ireland, advance decisions are not covered by statute but it is likely they are covered by common law.</li><li><strong>Advance refusals of treatment (sometimes called an advance directive) </strong>are clear instructions refusing certain or all medical procedures (for example mechanical ventilation or cardiopulmonary resuscitation) in a predefined future situation.<ul><li>To be valid the advance decision must be specific about the treatment that is being refused and the circumstances in which the refusal will apply.</li><li>Advance refusals of treatment are legally binding (under common law) if:<ul><li>The person is an adult, and</li><li>Was competent and fully informed when making the decision, and</li><li>The decision is clearly applicable to the current circumstances, and</li><li>There is no reason to believe that they have since changed their mind.</li></ul></li></ul></li><li><strong>Advance requests for specific treatment</strong> are statements authorising or requesting specific procedures.<ul><li>Advance requests for treatment are not legally binding but should be taken into account when assessing the person’s best interests.</li></ul></li><li>Further information is available in the '<a data-hyperlink-id=\"d9746bf3-141a-4f3a-ad64-ab13013c4691\" href=\"https://www.gov.uk/government/publications/mental-capacity-act-code-of-practice\" target=\"_blank\">Mental Capacity Act 2005 Code of Practice</a>' available at <a data-hyperlink-id=\"491221da-1d86-4c30-a58c-ab13013c46cd\" href=\"http://www.gov.uk/\" target=\"_blank\">www.gov.uk</a> and the section on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/diagnosis/assessment/#mental-capacity-act-2005\">Legal framework for decisions related to mental capacity</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a>.</li></ul><!-- end field 8e0730d2-ce36-40b1-bb98-cf049b9a15d6 --><!-- end item 1b892351-c177-4916-a9f8-b7209e4b1989 -->","subChapters":[]},{"id":"909c3184-9e12-56d5-b848-b04681a1fe06","slug":"basis-for-recommendation-b8c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9e28cf6d-f0a7-486f-85d1-cb7e94c01b28 --><h4>Basis for recommendation</h4><!-- end field 9e28cf6d-f0a7-486f-85d1-cb7e94c01b28 -->","summary":null,"htmlStringContent":"<!-- begin item b8c5e3bd-7da5-41a3-93e8-b46ae65eb0cf --><!-- begin field 28c6d094-9af0-4fa3-ac45-3c5ef096421f --><p>The recommendations on how to manage a person with end-stage chronic obstructive pulmonary disease (COPD) are based on clinical guidelines <em>British Thoracic Society (BTS) guidelines for home oxygen use in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Hardinge, 2015</a>], <em>Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019 report</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>].</p><h5>Simple measures for breathlessness</h5><ul><li>Clinical guidance from the BTS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Hardinge, 2015</a>], GOLD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] recommend simple measures such as fan therapy.</li></ul><h5>Opiates for breathlessness</h5><ul><li>Guidance from BTS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Hardinge, 2015</a>], GOLD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] recommend consideration of opiates for people with end-stage disease for relief of breathlessness which has not responded to other medical therapy.</li><li>In addition, NICE guidance states that when appropriate, benzodiazepines, tricyclic antidepressants, major tranquillisers and oxygen can be used for breathlessness in end-stage COPD that is unresponsive to other medical therapy. Guidance from GOLD states that there is no evidence of a beneficial effect from benzodiazepines.</li></ul><h5>Oxygen for breathlessness</h5><ul><li>Guidance from GOLD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>] and NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019a</a>] is in agreement that oxygen can be considered in people with end-stage disease for relief of breathlessness which has not responded to other medical therapy.</li><li>The BTS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Hardinge, 2015</a>] recommend that people with end-stage cardiorespiratory disease who have intractable breathlessness should not receive treatment with pulsed oxygen therapy (POT) if they are non-hypoxaemic or have mild levels of hypoxaemia above long term oxygen therapy (LTOT) thresholds (SpO2 ≥92%). Non-pharmacological treatments (such as fan therapy) and assessment for a trial of opiates should be considered.</li></ul><h5>Nutritional support</h5><ul><li>Guidance from GOLD recommends nutritional support in malnourished people with COPD — low BMI is associated with worse outcomes and nutritional supplementation can help with weight gain improving respiratory muscle strength and quality of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>].</li></ul><h5>Advance care planning and advance decisions</h5><ul><li>The information on advance care planning and advance decisions is taken from the <em>General Medical Council, Treatment and care towards the end of life: good practice in decision making </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GMC, 2010</a>] and the NICE guidelines on <em>Decision-making and mental capacity (NG108</em>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2018b</a>] and <em>End of life care for adults: service delivery (NG142)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">NICE, 2019c</a>].</li><li>The statement in relation to the potentially limited usefulness of advance decisions in COPD is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Halpin et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Spathis and Booth, 2008</a>] and from previous external reviewers of this CKS topic.</li></ul><!-- end field 28c6d094-9af0-4fa3-ac45-3c5ef096421f --><!-- end item b8c5e3bd-7da5-41a3-93e8-b46ae65eb0cf -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}